研究人員發(fā)現(xiàn)，染色體3p21.1上的一種遺傳變異增加了主要情緒性疾病發(fā)生的風(fēng)險,，如雙相型障礙癥（躁狂抑郁性精神病）和重性抑郁癥,，新成果發(fā)表在1月在線出版的《自然—遺傳學(xué)》期刊上,，它支持了這樣一種理論：影響雙相型障礙癥和重性抑郁癥的遺傳變異有重疊的地方。
雙相型障礙癥和重性抑郁癥是兩種類型廣泛的情緒疾病,，世界上幾百萬人受此影響,。重性抑郁癥的特征表現(xiàn)為悲觀和自我評價低下、失去壓力,、睡眠和食欲被擾亂,、能量低、注意力不集中等,。雙相型障礙癥是指抑郁期和狂躁期的交替出現(xiàn),。狂躁期的行為包括幻覺,、過度活躍,、精神旺盛和無休無止的行動。兩相型障礙癥和重性抑郁癥都有高風(fēng)險的自殺率,。
Francis McMahon和同事合作,，對大約7000名有某種嚴(yán)重情緒疾病的患者進行了金屬分析。他們發(fā)現(xiàn),，染色體3p21的遺傳變異與嚴(yán)重情緒疾病的發(fā)生風(fēng)險率增加有關(guān),。（生物谷Bioon.com）
生物谷推薦原始出處：
Nature Genetics 42, 128 - 131 (2010) 17 January 2010 | doi:10.1038/ng.523
Meta-analysis of genome-wide association data identifies a risk locus for major mood disorders on 3p21.1
Francis J McMahon1, Nirmala Akula1, Thomas G Schulze1,2, Pierandrea Muglia3,4, Federica Tozzi3, Sevilla D Detera-Wadleigh1, C J M Steele1, René Breuer2, Jana Strohmaier2, Jens R Wendland1, Manuel Mattheisen5,6,7, Thomas W Mühleisen5,6, Wolfgang Maier8, Markus M N?then5,6, Sven Cichon5,6, Anne Farmer9, John B Vincent4, Florian Holsboer10, Martin Preisig11 & Marcella Rietschel2,6 for the Bipolar Disorder Genome Study (BiGS) Consortium12
The major mood disorders, which include bipolar disorder and major depressive disorder (MDD), are considered heritable traits, although previous genetic association studies have had limited success in robustly identifying risk loci. We performed a meta-analysis of five case-control cohorts for major mood disorder, including over 13,600 individuals genotyped on high-density SNP arrays. We identified SNPs at 3p21.1 associated with major mood disorders (rs2251219, P = 3.63 × 10?8; odds ratio = 0.87; 95% confidence interval, 0.83–0.92), with supportive evidence for association observed in two out of three independent replication cohorts. These results provide an example of a shared genetic susceptibility locus for bipolar disorder and MDD.
1 Unit on the Genetic Basis of Mood & Anxiety Disorders, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA.
2 Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Mannheim, Germany.
3 Neurosciences Centre of Excellence in Drug Discovery, GlaxoSmithKline Research and Development, Verona, Italy.
4 Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
5 Department of Genomics, Life & Brain Center, Bonn, Germany.
6 Institute of Human Genetics, University of Bonn, Bonn, Germany.
7 Institute of Medical Biometry, Informatics, and Epidemiology, University of Bonn, Bonn, Germany.
8 Department of Psychiatry, University of Bonn, Bonn, Germany.
9 Institute of Psychiatry, King's College London, London, UK.
10 Max Planck Institute of Psychiatry, Munich, Germany.
11 University Hospital Center and University of Lausanne, Department of Psychiatry, Lausanne, Switzerland.
12 A full membership list is provided in the Supplementary Note.
